The therapeutic efficacy and safety profile of the novel PD‐1 inhibitor camrelizumab, when used alongside chemotherapy, was assessed in advanced NSCLC of both nonsquamous and squamous histologies through two randomized Phase 3 clinical trials, termed CameL and CameL‐sq, respectively [40, 41]. Here, PDCD1 is linked to non-small cell lung carcinoma.